UK's Claret Capital raises €575m for European biotechs
London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."
Novo Nordisk's IL-6 drug flunks two more heart trials
Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
Novartis hit as Lp(a) drug fails cardio outcomes trial
Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.
Cyber resilience: Protecting tomorrow's therapies before the...
As investors place increasing emphasis on operational maturity alongside scientific excellence, cyber resilience must become part of the conversation.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Better Antifibrotic Decisions Through Cross-Organ Insights
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development
10th Dermatology Drug Development Summit
The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflam
World Novel Drug Discovery Summit South Korea
Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities
2nd World-RNA Based Therapeutics & Vaccines Summit South Kor...
Korea’s Forum to Advance mRNA, CircRNA & saRNA Medicines for Clinical & Commercial Readiness
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting